Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
RP2/?RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Complete Title: A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination with Atezolizumab and Bevacizumab for the Treatment of Patients with Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma
Trial Phase: II
Investigator: Rachael Safyan
This is an open-label, nonrandomized, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
Keywords:
- Colorectal Neoplasms
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Rachael Safyan
RG1123588
NCT05733611
A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination with Atezolizumab and Bevacizumab for the Treatment of Patients with Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma
Colorectal Neoplasms